DiscoverThe Syneos Health PodcastPsychedelics 3.0: Challenges and Opportunities in an Evolving Field
Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

Update: 2024-10-30
Share

Description

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications.

 

Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments.

 

Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds.

 

For more from our neuroscience experts, check out these insights:

 

Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

Artificial Intelligence and Alzheimer’s: Transforming Patient Screening with Predictive Models

WEBINAR | Psychedelics 3.0: Challenges and Opportunities

Syneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical Development

BLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient’s Voice



The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing, Lindsay Crampton and Dr. Aaron Koenig